Related Experiment Video
Updated: Aug 22, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Product selection issues in the management of hemophilia B
1Great Plains Hemophilia Treatment Center, Iowa City, Iowa, USA. Jorge-dipaola@uiowa.edu
Issues that may influence selection of a factor concentrate for treatment of patients with hemophilia B, including whether the product is derived from plasma or is of recombinant origin, costs, pharmacokinetic issues, and safety considerations, are discussed in this paper. Data in the published literature, advice from the medical team, and patient and family preferences, will also impact product choice. Plasma-derived and recombinant products have similar efficacy; however, recombinant concentrates are more expensive and have demonstrated lower post-infusion recovery, and plasma-derived concentrates may be perceived as less safe. Improvements in donor selection and testing, viral inactivation, and product purification have greatly reduced potential risks of plasma-derived products. It is expected that both recombinant and plasma-derived products will continue to be used worldwide in the treatment of hemophilia B.
Issues that may influence selection of a factor concentrate for treatment of patients with hemophilia B, including whether the product is derived from plasma or is of recombinant origin, costs, pharmacokinetic issues, and safety considerations, are discussed in this paper. Data in the published literature, advice from the medical team, and patient and family preferences, will also impact product choice. Plasma-derived and recombinant products have similar efficacy; however, recombinant concentrates are more expensive and have demonstrated lower post-infusion recovery, and plasma-derived concentrates may be perceived as less safe. Improvements in donor selection and testing, viral inactivation, and product purification have greatly reduced potential risks of plasma-derived products. It is expected that both recombinant and plasma-derived products will continue to be used worldwide in the treatment of hemophilia B.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Venous Thrombosis III: Interprofessional Care
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
